greater/tyrosine

FIELD OF THE INVENTION The present invention provides a tyrosine ligation process and the crosslinking agents used to form tyrosine-containing polypeptide conjugates. BACKGROUND Conjugation has been widely used to optimize the properties of biologically active proteins, such as protein/peptide

TECHNICAL FIELD This invention relates to inhibitors of protein tyrosine phosphatase 1B (PTP1B) and other protein tyrosine phosphatases (PTPases). BACKGROUND Protein tyrosine phosphatases (PTPases) are a large family of diverse molecules that can play an important role in modulating a wide variety

BACKGROUND OF THE INVENTION An autoimmune disease results from an inappropriate immune response directed against a self antigen (an autoantigen), which is a deviation from the normal state of self-tolerance. Self-tolerance arises when the production of T cells and B cells capable of reacting against

BACKGROUND OF THE INVENTION An autoimmune disease results from an inappropriate immune response directed against a self antigen (an autoantigen), which is a deviation from the normal state of self-tolerance. Self-tolerance arises when the production of T cells and B cells capable of reacting against

The present invention relates to the field of processing casein-based materials. More particularly, it has for its object a method involving treatment of phosphocaseinates of monovalent cations or derivatives thereof. The invention also relates to the products obtained by such a method, especially

BACKGROUND OF THE INVENTION 1. Summary of the Invention In accordance with the present invention, there are provided fully human contiguous heavy and light chain sequences spanning the complementarity determining regions monoclonal antibodies against human epidermal growth factor receptor (EGF-r).

BACKGROUND OF THE INVENTION 1. Summary of the Invention In accordance with the present invention, there are provided fully human contiguous heavy and light chain sequences spanning the complementarity determining regions monoclonal antibodies against human epidermal growth factor receptor (EGF-r).

FIELD OF THE INVENTION The invention relates to the field of industrial microbiology. More specifically, methods for the enhancement of yield and rate of production of aromatic carboxylic acids such as para-hydroxycinnamic acid and cinnamic acid are disclosed. BACKGROUND OF THE

1. FIELD OF THE INVENTION The present invention relates to methods for the treatment of fibromyalgia syndrome, chronic fatigue syndrome, and pain. In particular, the present invention relates to methods of treating fibromyalgia syndrome, chronic fatigue syndrome, and pain with a sub-class of dual

FIELD OF THE INVENTION The present invention relates to benefit delivery particles which have higher deposition efficiency on tip hair. Moreover, the present invention also relates to composition comprising the particles and process for the production of the particles. BACKGROUND OF THE

BACKGROUND Congenital abnormalities of the kidney and the urinary tract (CAKUT) are the most common cause of pediatric kidney failure. These disorders are highly heterogenous, and their etiology is poorly understood. Many forms of CAKUT are familial, but because they may be asymptomatic, they

FIELD OF THE INVENTION The present invention concerns the synthesis of soluble forms of melanin and their composition, and methods of using such compositions to provide a natural-appearing tan to mammalian skin and hair and to provide a sun-screen, to treat hypopigmentation, to tint glass and

Field of the Invention The present invention concerns the synthesis of soluble forms of melanin and their composition, and methods of using such compositions to provide a natural-appearing tan to mammalian skin and hair and to provide a sun-screen, to treat hypopigmentation, to tint glass and

This invention relates to the supplementation of dietary proteins with a selected blend of four essential amino acids to improve their biologic value and net protein utilization. Nutritionists have established that several amino acids are essential for normal growth and well-being in animals,